Target 2035 – update on the quest for a probe for every protein

Susanne Müller, Suzanne Ackloo, Arij Al Chawaf, Bissan Al‐Lazikani, Albert A. Antolín, Jonathan B. Baell, Hartmut Beck, Shaunna Beedie, Ulrich A. K. Betz, G.a. Bezerra, Paul E. Brennan, David A. Brown, Peter J. Brown, Alex N. Bullock, Adrian J. Carter, A. Chaikuad, Mathilde Chaineau, Alessio Ciulli, Ian Collins, Jan Dreher, David H. Drewry, Kristina Edfeldt, A.m. Edwards, Ursula Egner, Stephen V. Frye, Stephen M. Fuchs, Matthew D. Hall, Ingo V. Hartung, Alexander Hillisch, Stephen Hitchcock, Evert Homan, Natarajan Kannan, James R. Kiefer, Stefan Knapp, Milka Kostić, Stefan Kubicek, Andrew R. Leach, S. Lindemann, Brian D. Marsden, Hisanori Matsui, Jordan L. Meier, Daniel Merk, Maurice Michel, Maxwell R. Morgan, Anke Mueller‐Fahrnow, Dafydd R. Owen, Benjamin Perry, Saul H. Rosenberg, Kumar Singh Saikatendu, Matthieu Schapira, Cora Scholten, Sujata Sharma, Anton Simeonov, M. Sundström, Giulio Superti‐Furga, Matthew H. Todd, Claudia Tredup, Masoud Vedadi, F. von Delft, Timothy M. Willson, Georg Winter, Paul Workman, C.h. ArrowsmithRSC 2021 · DOI · OpenAlex

Abstract

Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome remains fragmented. While genomics provides a "parts list," proteins are the primary executors of biological function. Understanding biology in health and disease requires a deep dive into protein function. Currently, approximately 35% of the human proteome remains uncharacterized, and less than 5% has been successfully targeted for drug discovery. Target 2035 is an international federation of biomedical scientists aiming to bridge this gap by developing chemogenomic libraries, chemical probes, and biological probes for the entire human proteome by the year 2035.

The Challenge of the Dark Proteome

Since the mapping of the human genome, a frustrating paradox has emerged: we have identified roughly 20,000 protein-coding genes, yet medical research remains fixated on a tiny sliver of them. This "dark proteome"—the 35% of proteins that remain completely uncharacterized—represents a massive untapped potential for therapeutic intervention.

The primary bottleneck is a lack of tools. To understand a protein’s function, researchers require "probes"—small molecules or antibodies that can selectively bind to and modulate that protein in a living cell. Without these tools, many potentially life-saving drug targets remain "undruggable." Target 2035 addresses this profound disconnect between genetic information and the development of effective medicines.

Target 2035: A global initiative to create a probe for every human protein by 2035.

The Target 2035 Mission

Target 2035 is not a single laboratory but a global "federation" of scientists from both public and private sectors. Operating under an Open Science framework, the initiative employs several key strategies to illuminate the proteome:

  • Chemogenomic Libraries: Rather than the traditional "one drug, one protein" approach, researchers are building vast libraries designed to cover entire protein families, such as kinases or solute carriers. The EUbOPEN set, for instance, comprises approximately 5,000 compounds.
  • AI-Guided Discovery: Machine learning and computational modeling are heavily leveraged to predict how molecules will bind to previously unstudied protein folds, accelerating the discovery process.
  • Open Chemistry Networks: This crowdsourcing model allows the global chemistry community to contribute synthetic ideas and laboratory space. In exchange, they receive biological evaluation data, with all findings shared under Creative Commons licenses.

A Phased Roadmap

The initiative follows a strategic timeline:

  • Phase I (2020–2025): Focuses on "druggable" proteins, building necessary infrastructure, and collecting existing pharmacological modulators.
  • Phase II (2025–2035): Will pivot toward the "undruggable" targets, requiring breakthroughs in technologies like PROTACs (protein degraders) and covalent ligand screening.

Collaborative Data Ecosystems

Several critical data repositories and consortia feed into the Target 2035 ecosystem, ensuring high-quality research:

  • The Chemical Probes Portal: An expert-curated database that scores the quality of available probes. This ensures researchers avoid "dirty" or non-selective molecules that lead to irreproducible results.
  • Pharos/IDG (Illuminating the Druggable Genome): A platform mapping knowledge gaps in key families like GPCRs, kinases, and ion channels.
  • EUbOPEN and ReSOLUTE: Massive partnerships aimed at providing freely available sets of high-quality chemogenomic tools and unlocking specific families like solute carrier (SLC) transporter proteins.

Key Insights: Quality and Openness

A major realization in the field is that poor-quality chemical tools are a primary driver of irreproducible science. Target 2035 emphasizes rigorous validation—including selectivity, potency, and cell activity—for every probe produced.

The "COVID Moonshot" served as a powerful inspiration, proving that the scientific community can work at a "proteome scale" when intellectual property barriers are lowered. By creating probes first, the initiative defines the "druggability" of the future. For example, the Structural Genomics Consortium (SGC) is using WD40 repeat (WDR) proteins—a large, disease-associated family—as a pilot to prove that AI-guided, open-source pipelines can rapidly illuminate "dark" protein families.

Current Progress and Future Outlook

While Target 2035 is a long-term mission, significant momentum has already been achieved:

  • Infrastructure Growth: The Chemical Probes Portal now features over 600 compounds covering 300 targets.
  • Library Expansion: The EUbOPEN project is on track to cover roughly one-third of the currently "druggable" genome.
  • Pilot Success: Early results from the WDR project demonstrate that integrated, open pipelines are more efficient than traditional "closed" pharmaceutical models.

However, the path forward is challenging. Moving from 300 targets to 20,000 requires massive logistical and financial support. Phase II will require technological breakthroughs to target "intrinsically disordered" proteins that lack obvious binding pockets. Furthermore, maintaining open-access databases and physical repositories requires long-term funding that transcends typical grant cycles. Despite these hurdles, Target 2035 represents a transformative shift toward a more comprehensive and collaborative understanding of human biology.

Summary updated

Abstract

Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. The challenge of translating the wealth of new knowledge from genomics into new medicines is that proteins, and not genes, are the primary executers of biological function. Therefore, much of how biology works in health and disease must be understood through the lens of protein function. Accordingly, a subset of human proteins has been at the heart of research interests of scientists over the centuries, and we have accumulated varying degrees of knowledge about approximately 65% of the human proteome. Nevertheless, a large proportion of proteins in the human proteome (∼35%) remains uncharacterized, and less than 5% of the human proteome has been successfully targeted for drug discovery. This highlights the profound disconnect between our abilities to obtain genetic information and subsequent development of effective medicines. Target 2035 is an international federation of biomedical scientists from the public and private sectors, which aims to address this gap by developing and applying new technologies to create by year 2035 chemogenomic libraries, chemical probes, and/or biological probes for the entire human proteome.
BibTeX
@inproceedings{muller2021target,
  author = {Susanne Müller and Suzanne Ackloo and Arij Al Chawaf and Bissan Al‐Lazikani and Albert A. Antolín and Jonathan B. Baell and Hartmut Beck and Shaunna Beedie and Ulrich A. K. Betz and G.A. Bezerra and Paul E. Brennan and David A. Brown and Peter J. Brown and Alex N. Bullock and Adrian J. Carter and A. Chaikuad and Mathilde Chaineau and Alessio Ciulli and Ian Collins and Jan Dreher and David H. Drewry and Kristina Edfeldt and A.M. Edwards and Ursula Egner and Stephen V. Frye and Stephen M. Fuchs and Matthew D. Hall and Ingo V. Hartung and Alexander Hillisch and Stephen Hitchcock and Evert Homan and Natarajan Kannan and James R. Kiefer and Stefan Knapp and Milka Kostić and Stefan Kubicek and Andrew R. Leach and S. Lindemann and Brian D. Marsden and Hisanori Matsui and Jordan L. Meier and Daniel Merk and Maurice Michel and Maxwell R. Morgan and Anke Mueller‐Fahrnow and Dafydd R. Owen and Benjamin Perry and Saul H. Rosenberg and Kumar Singh Saikatendu and Matthieu Schapira and Cora Scholten and Sujata Sharma and Anton Simeonov and M. Sundström and Giulio Superti‐Furga and Matthew H. Todd and Claudia Tredup and Masoud Vedadi and F. von Delft and Timothy M. Willson and Georg Winter and Paul Workman and C.H. Arrowsmith and Brian Marsden},
  title = {{Target 2035 – update on the quest for a probe for every protein}},
  booktitle = {RSC},
  year = {2021},
  doi = {10.1039/d1md00228g},
}
Figure